Perspective from Lisa M. Young, OD, FAAO
Source/Disclosures
Disclosures: Denis reports serving as a consultant for Novartis, Laboratoires Thea, EyeTechCare, Aerie and iStar. Please see the study for all other author’s relevant financial disclosures.
June 29, 2020
1 min read
Save

Glaucoma patients satisfied with multi-dose drug delivery system

Perspective from Lisa M. Young, OD, FAAO
Source/Disclosures
Disclosures: Denis reports serving as a consultant for Novartis, Laboratoires Thea, EyeTechCare, Aerie and iStar. Please see the study for all other author’s relevant financial disclosures.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The use of a multi-dose delivery system for treating glaucoma was highly accepted by patients with decreased visual acuity and dexterity problems, according to a study published in the European Journal of Ophthalmology.

“While safe and effective topical treatments for glaucoma exist, insufficient treatment compliance may impact on the treatment success,” Philippe Denis, MD, PhD, service d’ophtalmologie, Hopital de la Croix-Rouss, and colleagues wrote. “Patients with instilling problems of their topical glaucoma medication due to vision or dexterity problems are acknowledged to be at higher risk for poor compliance, frequent medication switching and, ultimately, surgery.”

In an observational, retrospective and non-interventional study assessing patient satisfaction and ease of multi-dose delivery system (MDDS) use, 788 adult patients underwent analysis between 2016 and 2018. They attended a single study visit and then filled out an independent questionnaire regarding the use of the MDDS.

Overall, 78.4% of patients rated the MDDS as good, better or much better than their previous treatment options, 78.3% were satisfied or very satisfied, and 82.8% said they would continue using this delivery system. Non-serious adverse events were reported by 0.97% of patients and were resolved in most cases.

“The tested MDDS is highly accepted in the studied population and is a suitable choice for a xed-combination glaucoma therapy,” Denis and colleagues concluded. “Further studies may be necessary to assess the easiness of use of this easy-to-grip delivery system in patients with greater disability to instill or having severe problems in instilling their eye drops themselves.”